source
- Pharvaris reports 83% drop in hereditary angioedema attacks in phase 3 trial, FDA decision pendingPharvaris announced that its oral bradykinin B2 receptor antagonist, deucrictibant, met the primary goal in a second phase 3 study. The trial, called CHAPTER-3, enrolled 85 patients with three for…
- BMC Medical recalls 20,160 Luna G3 APAP devices over firmware defect, class I recallBMC Medical Co., Ltd. announced a recall of its Luna G3 APAP (Model LG3600) devices that were distributed in the United States after identifying a firmware defect. The defect was linked to firmwar…